Efficacy of treating advanced non-small cell lung cancer with autologous cytokine-induced killer cells

Objective To study the efficacy of treating advanced non-small cell lung cancer(NSCLC) with autologous cytokine-induced killer(CIK)cells combined with chemotherapy combined with biotherapy.Methods Fifty-nine advanced NSCLC patients were divited into group A(TP chemotherapy alone) and group B(TP chemotherapy plus autologous CIK biotherapy).The quality of life,host cellular immune response,remission rate(RR),time to progression and median survival time were investigated and compared between the two groups.CIK cells were induced from autologous peripheral mononuclear cells.Results Amounts and cytotoxic activity of CIK cells reached the peak level between days 14 to 21.Compared to group A,the host immune function and quality of life in group B were significantly improved.Conclusion Chemotherapy combined with CIK cells can effectively improve the immune function.